Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Partially desulfated heparin modulates the interaction between anti-protamine/heparin antibodies and platelets.

Jouni R, Zöllner H, Khadour A, Wesche J, Grotevendt A, Brandt S, Delcea M, Krauel K, Schwertz H, Sachs UJ, Greinacher A, Bakchoul T.

Thromb Haemost. 2016 Jan;115(2):324-32. doi: 10.1160/TH15-07-0539. Epub 2015 Oct 1.

PMID:
26423467
2.

Platelet activation in the presence of neutral protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes.

Zöllner H, Jouni R, Panzer S, Khadour A, Janzen L, Wesche J, Ten Berg M, Schellong S, Heinken A, Greinacher A, Bakchoul T.

J Thromb Haemost. 2017 Jan;15(1):176-184. doi: 10.1111/jth.13547. Epub 2016 Nov 30.

3.

Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.

Krauel K, Hackbarth C, Fürll B, Greinacher A.

Blood. 2012 Feb 2;119(5):1248-55. doi: 10.1182/blood-2011-05-353391. Epub 2011 Nov 2.

4.

High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Lee GM, Welsby IJ, Phillips-Bute B, Ortel TL, Arepally GM.

Blood. 2013 Apr 11;121(15):2828-35. doi: 10.1182/blood-2012-11-469130. Epub 2013 Feb 19.

5.

Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH).

Joglekar MV, Quintana Diez PM, Marcus S, Qi R, Espinasse B, Wiesner MR, Pempe E, Liu J, Monroe DM, Arepally GM.

Thromb Haemost. 2012 Apr;107(4):717-25. doi: 10.1160/TH11-11-0795. Epub 2012 Feb 8.

6.

Incidence of antibodies to protamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcome.

Pouplard C, Leroux D, Rollin J, Amiral J, May MA, Gruel Y.

Thromb Haemost. 2013 Jun;109(6):1141-7. doi: 10.1160/TH12-11-0844. Epub 2013 May 2.

PMID:
23636177
7.

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.

Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, Prestwich GD, MacArthur RB, Walters BB, Hoidal JR, Kennedy TP.

Am J Physiol Cell Physiol. 2010 Jul;299(1):C97-110. doi: 10.1152/ajpcell.00009.2010. Epub 2010 Apr 7.

8.

Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine/heparin antibodies.

Bakchoul T, Jouni R, Warkentin TE.

J Thromb Haemost. 2016 Sep;14(9):1685-95. doi: 10.1111/jth.13405. Epub 2016 Aug 29. Review.

9.

Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis.

Bakchoul T, Zöllner H, Amiral J, Panzer S, Selleng S, Kohlmann T, Brandt S, Delcea M, Warkentin TE, Sachs UJ, Greinacher A.

Blood. 2013 Apr 11;121(15):2821-7. doi: 10.1182/blood-2012-10-460691. Epub 2013 Jan 16.

10.

Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.

Ahmad S, Jeske WP, Walenga JM, Aldabbagh A, Iqbal O, Fareed J.

Thromb Res. 2000 Oct 1;100(1):47-54.

PMID:
11053616
11.

Titrimetric method for determination of O-desulfated heparin in physiological samples using protamine-sensitive membrane electrode as endpoint detector.

Buchanan SA, Kennedy TP, MacArthur RB, Meyerhoff ME.

Anal Biochem. 2005 Nov 15;346(2):241-5. Epub 2005 Sep 15.

PMID:
16213460
12.

Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.

Prechel MM, Jeske WP, Walenga JM.

Thromb Res. 2010 Apr;125(4):e143-8. doi: 10.1016/j.thromres.2009.10.021.

PMID:
19931120
13.

Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia.

Nazi I, Arnold DM, Warkentin TE, Smith JW, Staibano P, Kelton JG.

J Thromb Haemost. 2015 Oct;13(10):1900-7. doi: 10.1111/jth.13066. Epub 2015 Aug 29.

14.

Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.

Untch B, Ahmad S, Messmore HL, Schultz CL, Ma Q, Hoppensteadt DA, Walenga JM, Fareed J.

Thromb Res. 2002 Apr 15;106(2):149-56.

PMID:
12182915
15.

Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M.

Blood. 2006 Mar 15;107(6):2346-53. Epub 2005 Nov 22.

16.

Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.

Krauel K, Fürll B, Warkentin TE, Weitschies W, Kohlmann T, Sheppard JI, Greinacher A.

J Thromb Haemost. 2008 Dec;6(12):2160-7. doi: 10.1111/j.1538-7836.2008.03171.x. Epub 2008 Oct 3.

17.

Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive.

Selleng S, Malowsky B, Strobel U, Wessel A, Ittermann T, Wollert HG, Warkentin TE, Greinacher A.

J Thromb Haemost. 2010 Jan;8(1):30-6. doi: 10.1111/j.1538-7836.2009.03626.x. Epub 2009 Sep 28.

19.

Heparins with reduced anti-coagulant activity reduce myocardial reperfusion injury.

Barry WH, Kennedy TP.

Recent Pat Cardiovasc Drug Discov. 2011 May;6(2):148-57. Review.

PMID:
21453252
20.

Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Padmanabhan A, Jones CG, Bougie DW, Curtis BR, McFarland JG, Wang D, Aster RH.

Blood. 2015 Jan 1;125(1):155-61. doi: 10.1182/blood-2014-06-580894. Epub 2014 Oct 23.

Supplemental Content

Support Center